Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Secreted, extracellular space, extracellular matrix. Secreted, extracellular space, surface film. |
Domain |
PF00059 Lectin C-type domain |
Function |
In presence of calcium ions, it binds to surfactant phospholipids and contributes to lower the surface tension at the air-liquid interface in the alveoli of the mammalian lung and is essential for normal respiration. |
Biological Process |
GO:0007585 respiratory gaseous exchange |
Molecular Function |
GO:0030246 carbohydrate binding |
Cellular Component |
GO:0005578 proteinaceous extracellular matrix GO:0005581 collagen trimer GO:0030135 coated vesicle GO:0030136 clathrin-coated vesicle GO:0030139 endocytic vesicle GO:0030141 secretory granule GO:0042599 lamellar body GO:0045334 clathrin-coated endocytic vesicle GO:0099503 secretory vesicle |
KEGG |
hsa04145 Phagosome |
Reactome |
R-HSA-5619084: ABC transporter disorders R-HSA-5683678: Defective ABCA3 causes pulmonary surfactant metabolism dysfunction type 3 (SMDP3) R-HSA-5688890: Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4) R-HSA-5688849: Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5) R-HSA-5687868: Defective SFTPA2 causes idiopathic pulmonary fibrosis (IPF) R-HSA-1643685: Disease R-HSA-5687613: Diseases associated with surfactant metabolism R-HSA-5668914: Diseases of metabolism R-HSA-5619115: Disorders of transmembrane transporters R-HSA-392499: Metabolism of proteins R-HSA-5683826: Surfactant metabolism |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between SFTPA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of SFTPA2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of SFTPA2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of SFTPA2 in various data sets.
|
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SFTPA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SFTPA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SFTPA2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SFTPA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of SFTPA2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between SFTPA2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | SFTPA2 |
Name | surfactant protein A2 |
Aliases | SP-A2; COLEC5; surfactant, pulmonary-associated protein A2A; surfactant, pulmonary-associated protein A2; SP ...... |
Chromosomal Location | 10q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting SFTPA2 collected from DrugBank database. |
There is no record. |